As a National Clinic Trials Network Lead Academic Participating Site, we hope to accomplish the following: 1. To provide scientific leadership and intellectual input in the creation of thoughtful, feasible trials to improve the health of cancer patients. We will accomplish this aim through the ongoing participation in clinical trials that spn the spectrum of disease-specific and radiation and surgical oncology;by applying the UNC culture of multidisciplinary care to make NCTN trials stronger and more modern;by leveraging the commitment of junior faculty, who will be the leaders of tomorrow; and by applying health services research in the development of clinical trials, including factors important to clinical outcomes, such as cost effectiveness, delivery of care, and policy. 2. To continue to be strong supporters of Network trials, through our rapidly growing clinical enterprise and robust accrual. We will support this aim by building on our historically strong accrual to CALGB, GOG, and ACOSOG trials and our well-funded and organized infrastructure, and through active participation across the NCTN. 3. To provide opportunities for excellent translational science embedded in NCTN clinical trials. UNC has a long commitment to translational science and has served as reference lab across multiple trials, with substantial (more than $3 million) investment in Next Generation sequencing and genomics;we are well suited to serve as a translational research collaborator for clinical trials in the future.

Public Health Relevance

The UNC Lineberger Lead Academic Participating Site brings together an accomplished group of academic clinical oncologists and faculty from related disciplines, organized into multidisciplinary disease-site groups, to undertake cutting edge clinical research across the spectrum of cancers. The UNC LAPS will commit the staff and professional resources to manage and evaluate these research activities, accrue patients, and share knowledge with the wider research community. This effort will serve to enhance the understanding of cancer progression and treatment, lead to new studies based on information learned, and improve outcomes for patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180838-01
Application #
8605733
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-07
Project End
2019-02-28
Budget Start
2014-05-07
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$623,050
Indirect Cost
$213,149
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599